CoChat

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer

Open access
Tjensvoll, Kjersti, Lapin, Morten, Buhl, Tove, Oltedal, Satu, Steen-Ottosen Berry, Katrine, Gilje, Bjørnar, Søreide, Jon Arne, Javle, Millind, Nordgård, Oddmund, Smaaland, Rune · 2016 · Molecular Oncology
Cited by 154

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

We used KRAS mutations to investigate the clinical relevance of circulating tumor DNA (ctDNA) measurements in patients with advanced pancreatic cancer. Fifty‐three blood samples were collected from 14 prospectively recruited patients prior to chemotherapy (gemcitabine or FOLFIRINOX) and subsequently every month during treatment. Samples were processed by density centrifugation and plasma DNA isolation. A Peptide–nucleic acid–clamp PCR was then used to detect KRAS mutations (present in >90% of pancreatic cancers) as a surrogate marker for ctDNA. Plasma samples from 29 healthy individuals were analyzed as a reference group. Results were compared to conventional monitoring measures and survival data. Median follow‐up time was 3.7 months (range 0.6–12.9 months). Ten (71%) patients had a positive KRAS status in the plasma samples obtained prior to chemotherapy, indicating the presence of ctDNA. Among the patients who were ctDNA‐positive before chemotherapy, nine (90%) experienced disease progression during follow‐up, compared to one (25%) of four ctDNA‐negative patients (P = 0.01). The pre‐therapy ctDNA level was a statistically significant predictor of both progression‐free and overall survival (P = 0.014 and 0.010, respectively). Of the 14 patients, ten had ≥2 follow‐up samples; in several of these patients, the ctDNA level changed substantially during the course of chemotherapy. Changes in ctDNA levels corresponded both with radiological follow‐up data and CA19‐9 levels for several patients. This pilot study supports the hypothesis that ctDNA may be used as a marker for monitoring treatment efficacy and disease progression in pancreatic cancer patients. Recruitment of more patients is ongoing to corroborate these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2015.11.012

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Steen-Ottosen Berry, K., Gilje, B., Søreide, J. A., Javle, M., Nordgård, O., & Smaaland, R.
Venue
Molecular Oncology
Publisher
Wiley
Published
2015-12-15
Volume
10
Issue
4
Pages
635-643
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2207038926
Cited by
154
References
13
FWCI
4.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.